A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma

Administered By

Awarded By

Contributors

Start/End

  • January 1, 2015 - December 31, 2022